Jacobs Levy Equity Management Inc. Purchases New Stake in Twist Bioscience Corporation $TWST

Key Points

• Jacobs Levy Equity Management Inc. acquired 42,323 shares of Twist Bioscience Corporation, worth approximately $1,662,000, increasing its ownership to about 0.07% of the company.
• Twist Bioscience recently reported earnings per share of ($0.47), beating estimates and generating revenue of $96.06 million for the quarter.
• Analysts have a consensus price target of $49.40 for Twist Bioscience, with nine analysts rating the stock as a "Buy."

Jacobs Levy Equity Management Inc. purchased a new stake in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 42,323 shares of the company's stock, valued at approximately $1,662,000. Jacobs Levy Equity Management Inc. owned approximately 0.07% of Twist Bioscience as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of the business. ARK Investment Management LLC grew its stake in shares of Twist Bioscience by 11.5% in the first quarter. ARK Investment Management LLC now owns 6,241,595 shares of the company's stock valued at $245,045,000 after acquiring an additional 645,730 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Twist Bioscience by 1.0% in the first quarter. Vanguard Group Inc. now owns 5,867,459 shares of the company's stock valued at $230,356,000 after acquiring an additional 60,276 shares in the last quarter. EdgePoint Investment Group Inc. acquired a new position in shares of Twist Bioscience in the first quarter valued at about $43,705,000. Nuveen LLC acquired a new position in shares of Twist Bioscience in the first quarter valued at about $31,960,000. Finally, American Century Companies Inc. grew its stake in shares of Twist Bioscience by 0.9% in the first quarter. American Century Companies Inc. now owns 763,406 shares of the company's stock valued at $29,971,000 after acquiring an additional 7,054 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Evercore ISI set a $46.00 price objective on shares of Twist Bioscience in a research report on Monday, August 4th. Cowen reissued a "buy" rating on shares of Twist Bioscience in a report on Monday, August 4th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Twist Bioscience presently has a consensus rating of "Moderate Buy" and a consensus target price of $49.40.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 2,265 shares of the firm's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $25.76, for a total transaction of $58,346.40. Following the completion of the transaction, the chief executive officer owned 634,740 shares in the company, valued at approximately $16,350,902.40. This trade represents a 0.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Adam Laponis sold 2,449 shares of the firm's stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $38.15, for a total transaction of $93,429.35. Following the sale, the chief financial officer directly owned 103,569 shares of the company's stock, valued at approximately $3,951,157.35. This trade represents a 2.31% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 8,911 shares of company stock valued at $288,159. Company insiders own 3.01% of the company's stock.

Twist Bioscience Trading Up 5.3%

Twist Bioscience stock traded up $1.36 during mid-day trading on Tuesday, hitting $27.08. 2,312,914 shares of the stock were exchanged, compared to its average volume of 1,322,669. The company has a quick ratio of 3.60, a current ratio of 3.90 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 12 month low of $24.07 and a 12 month high of $55.33. The firm's fifty day simple moving average is $30.12 and its two-hundred day simple moving average is $34.04. The stock has a market capitalization of $1.63 billion, a price-to-earnings ratio of -18.68 and a beta of 2.31.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.07. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. The firm had revenue of $96.06 million during the quarter, compared to analyst estimates of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.